Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HINT1 | P49773 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26534325 | 0.87 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1ALDH1A1HINT1 | |
| SCHEMBL26534322 | 0.87 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1ALDH1A1HINT1 | |
| SCHEMBL22704912 | 0.87 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1ALDH1A1HINT1 | |
| SCHEMBL24081125 | 0.84 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1ALDH1A1HINT1 | |
| SCHEMBL22883219 | 0.80 | TAS1R3 (0.62) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL21376697 | 0.80 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1ALDH1A1HINT1 | |
| SCHEMBL20434944 | 0.79 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1ALDH1A1HINT1 | |
| SCHEMBL18490364 | 0.79 | TAS1R3 (0.54) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL22034192 | 0.79 | TAS1R3 (0.54) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 | |
| SCHEMBL29881515 | 0.79 | TAS1R3 (0.54) | KDM4ETAS1R3TAS1R1HINT1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | KDM4E 3225/4885TAS1R3 2072/4885TAS1R1 1825/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | KDM4E 3225/4885TAS1R3 2072/4885TAS1R1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.